



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 45968

**Title:** ADAMT 3 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

**Reviewer's code:** 02533177

**Reviewer's country:** China

**Science editor:** Fang-Fang Ji

**Reviewer accepted review:** 2019-01-31 07:41

**Reviewer performed review:** 2019-02-01 08:31

**Review time:** 1 Day

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

There is an urgent clinical need to prediction of sorafenib response and prognosis in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment due to the potentially serious side effects of sorafenib in these patients. The authors found that the



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment. Though the sample size is not too large, the experimental design and statistic analysis was correct. It has some clinical reference values.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- [Y] No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- [Y] No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 45968

**Title:** ADAMT 3 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

**Reviewer’s code:** 01438231

**Reviewer’s country:** United States

**Science editor:** Fang-Fang Ji

**Reviewer accepted review:** 2019-01-31 16:08

**Reviewer performed review:** 2019-02-06 19:03

**Review time:** 6 Days and 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma In this paper, the authors examine the usefulness of vWF and ADAMTS13 measurements as biomarkers of



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

sorafenib effectiveness in treating hepatocellular carcinoma (HCC). Sorafenib treatment may be associated with serious side effects, hence, it would be useful to know when it will be effective and when it will not be effective. The authors conclude that the vWF/ADAMTS13 activity ratio is a useful biomarker for sorafenib response. ADAMTS13 activity is a useful prognostic indicator. A major issue with this study is the small sample size (n=41) and the fact that almost all the subjects were male. In fact, analysis was performed on the basis of gender in tables 2 and 3. Since only 3 subjects were female, how can this data be meaningful? In the Introduction, the authors discuss HCC, ADAMTS13 and sorafenib, but do not really explain how they are related to one another. Why would they think that ADAMTS13 and vWF would be useful biomarkers for sorafenib response? In the intro they state " Furthermore, blood coagulation cascade was demonstrated to be associated with cancer development[14,15]." They do not discuss this association any further. Are they suggesting that vWF and ADAMTS13 levels/activity affect coagulation and affect tumor progression? This should be presented more clearly in the intro. Also, they state "...we investigated the relationship between ADAMTS13 and VWF in patients with HCC receiving sorafenib treatment..." It is a minor detail, but I am guessing they mean ADAMTS13 and vWF levels. Or activity? VEGF levels are measured and analyzed, but the exact significance of these measurements is unclear? Is it another biomarker? In the discussion, the authors do a better job of discussing the possible mechanisms and associations between ADAMTS13, vWF and HCC. The analysis is acceptable and support the conclusions, but this is a small pilot study that suggest a relationship between ADAMTS13, vWF and HCC.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

[ ] The same title



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

Duplicate publication

Plagiarism

No

***BPG Search:***

The same title

Duplicate publication

Plagiarism

No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 45968

**Title:** ADAMT 3 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

**Reviewer's code:** 03270412

**Reviewer's country:** Turkey

**Science editor:** Fang-Fang Ji

**Reviewer accepted review:** 2019-02-12 03:59

**Reviewer performed review:** 2019-02-12 04:06

**Review time:** 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Ramicirumab has effective increased AFP level patients Is there any correlation between VEFR2 and increased AFP patients



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

**INITIAL REVIEW OF THE MANUSCRIPT**

*Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- [Y] No

*BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- [Y] No